Analysts expect UROGEN PHARMA (NASDAQ:URGN) to report sales of $7.67 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for UROGEN PHARMA’s earnings, with estimates ranging from $7.50 million to $8.00 million. The company is expected to report its next earnings report on Monday, November 13th.

According to Zacks, analysts expect that UROGEN PHARMA will report full-year sales of $7.67 million for the current year, with estimates ranging from $7.50 million to $8.00 million. For the next financial year, analysts expect that the firm will report sales of $0.00 per share. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow UROGEN PHARMA.

Several research firms have recently issued reports on URGN. Oppenheimer Holdings, Inc. set a $32.00 price target on shares of UROGEN PHARMA and gave the company a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research lowered shares of UROGEN PHARMA from a “buy” rating to a “hold” rating in a research report on Friday, August 18th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $26.00.

UROGEN PHARMA (NASDAQ:URGN) opened at 30.88 on Thursday. UROGEN PHARMA has a one year low of $13.01 and a one year high of $33.77. The company’s market capitalization is $401.75 million. The stock’s 50 day moving average is $26.18 and its 200 day moving average is $20.40.

Several hedge funds and other institutional investors have recently bought and sold shares of URGN. Spark Investment Management LLC bought a new stake in shares of UROGEN PHARMA in the second quarter valued at approximately $856,000. Menora Mivtachim Holdings LTD. bought a new stake in shares of UROGEN PHARMA in the second quarter valued at approximately $2,331,000. LLBH Private Wealth Management LLC bought a new stake in shares of UROGEN PHARMA in the second quarter valued at approximately $695,000. Alps Advisors Inc. bought a new stake in shares of UROGEN PHARMA in the second quarter valued at approximately $195,000. Finally, Jennison Associates LLC bought a new stake in shares of UROGEN PHARMA in the second quarter valued at approximately $3,168,000. 36.06% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/05/7-67-million-in-sales-expected-for-urogen-pharma-urgn-this-quarter-2.html.

UROGEN PHARMA Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on UROGEN PHARMA (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for UROGEN PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UROGEN PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.